Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Other Non-Current Liabilities (2018 - 2026)

TELA Bio has reported Other Non-Current Liabilities over the past 8 years, most recently at $1.5 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 6.26% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, up 6.26%, while the annual FY2025 figure was $1.5 million, 6.26% up from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $1.5 million at TELA Bio, down from $1.6 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $1.7 million in Q4 2023 and troughed at $8000.0 in Q1 2021.
  • A 5-year average of $1.2 million and a median of $1.3 million in 2022 define the central range for Other Non-Current Liabilities.
  • Biggest five-year swings in Other Non-Current Liabilities: soared 16925.0% in 2022 and later fell 18.78% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $380000.0 in 2021, then skyrocketed by 223.95% to $1.2 million in 2022, then soared by 36.88% to $1.7 million in 2023, then dropped by 17.51% to $1.4 million in 2024, then increased by 6.26% to $1.5 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for TELA at $1.5 million in Q4 2025, $1.6 million in Q3 2025, and $1.2 million in Q2 2025.